COLLISION Trial - Colorectal Liver Metastases: Surgery vs Thermal Ablation (COLLISION)

COLLISION Trial - Colorectal Liver Metastases: Surgery vs Thermal Ablation, a Phase III Single-blind Prospective Randomized Controlled Trial

The primary objective is to prove non-inferiority of thermal ablation compared to hepatic resection in patients with at least one resectable and ablatable colorectal liver metastases (≤3cm) and no extrahepatic disease.

Study Overview

• Status: Recruiting
• Conditions: Surgery; Liver Metastases; ColoRectal Cancer; Liver Metastasis Colon Cancer
• Intervention / Treatment: Procedure: Surgical resection; Procedure: Thermal ablation

Detailed Description

Study design:

COLLISION is a single-blind prospective multi-center phase-III randomized controlled trial. We hypothesize that thermal ablation is non-inferior to surgery for the selected patient groups in terms of the primary objective (overall survival). The Cox proportional hazards model (1-sided; non-inferiority or superiority) is used for sample size calculations. Given the superior safety profile we consider a hazard ratio of 1.3 to represent the upper limit of non-inferiority (non-inferiority margin). An HR of 1.3 corresponds to a 56.5% chance of the ablated patients to die first ((P = HR/(1 + HR) = 1.3/(1 + 1.3) = 0.565 (56.5%)). With 3 years of patient accrual and five years of follow-up we will have reached 60% of events (death) in approximately 6.5 years (overall probability of event, pE =0.6). The calculated sample size therefore is 599 (NS).To account for a 10% drop-out ratio (NDO=69) prior to randomization and a 3% loss to follow-up (NLTFU=18) after randomization we need to include 687 patients (NI). A total number of 618 patients will be randomized (NR) into one of two arms: arm A will undergo surgical resection (n=309) and arm B thermal ablation (n=309) for appointed target lesions.

Study population:

Patients with ≥1 resectable and ablatable CRLM (≤3cm), no extrahepatic disease and a good performance status (WHO 0-2) are considered eligible. Supplementary resections for resectable lesions >3cm and thermal ablations for unresectable CRLM ≤3cm are allowed with a maximum number of CRLM of 10.

Intervention:

Eligible patients will be stratified into low-, intermediate- and high disease burden after assessment by an expert panel. The panel, consisting of at least two diagnostic radiologists, two interventional radiologists and two hepatobiliary and/or oncological surgeons, will appoint lesions that are resectable and ablatable as target lesions, resectable and unablatable lesions as unablatable lesions and ablatable but unresectable lesions as unresectable lesions. All unablatable lesions should be resectable and all unresectable lesions should be ≤3cm and ablatable.

With the exception of patients that are suitable for laparoscopic resection or percutaneous ablation (low disease burden), eligibility needs to be reconfirmed during the surgical procedure. Hereafter patients will be randomized to undergo surgical resection of the target lesions (allowing thermal ablation for additional unresectable lesions) or thermal ablation (allowing resection for additional unablatable lesions). For open procedures randomization will be performed shortly after surgical inspection and IOUS with the patient under general anaesthesia. Both the experimenter(s) and the participant will be unaware of the eventual treatment arm prior to the procedure; after the procedure the patient will remain unaware (single-blind).

Conferring to national guidelines follow-up will include imaging, laboratory tests including tumour markers (CEA) and clinical examination every 3 months for the first year and every 6 months hereafter. Follow-up cross-sectional imaging should include at least an abdominal ceCT or upper abdominal ceMRI at the given time-points. Participating centres are free to add 18F-FDG PET-CTs at specific time-points or to use alternating specific modalities, as long as the follow-up protocol is pre-approved by the trial coordinators and as long as follow-up imaging is identical for both treatment arms. Quality of life questionnaires will be assessed at baseline, every 3 months for the first year and every 6 months hereafter accordingly.

Patients with recurrences that are considered unsuitable for additional focal therapy will be re-referred to their medical oncologist to assess additional systemic chemotherapy. In the event of chemotherapeutic down-staging hereafter, focal therapy can be reconsidered.

• Study Type: Interventional
• Enrollment (Anticipated): 618
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: RS Puijk, MD; Phone Number: 020 444 4444; Email: interventieradiologie@vumc.nl
• Study Contact Backup: Name: MR Meijerink, MD, PhD; Phone Number: 020 444 4444; Email: interventieradiologie@vumc.nl

Study Locations

• Netherlands
  • NH
    • Amsterdam, NH, Netherlands, 1081
      • Recruiting
      • Amsterdam University Medical Center - location VUmc
      • Contact: M.R. Meijerink, MD, PhD; Phone Number: 0204444444; Email: interventieradiologie@vumc.nl

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Most important inclusion criteria:

• At least one CRLM size ≤ 3 cm eligible for both surgical resection and thermal ablation (target lesions);
• Additional unresectable CRLM should be ≤ 3 cm and ablatable (unresectable lesions);
• Additional unablatable CRLM should be resectable (unablatable lesions);
• Maximum number of CRLM 10;
• Resectability and ablatability should be re-confirmed intra-operatively by US plus full exploration for hepatic, peritoneal and regional lymph node metastases;
• ASA 1-3.

Most important exclusion criteria:

• No target lesions suitable for both resection and ablation;
• Radical treatment unfeasible or unsafe (e.g. insufficient FLR);
• The presence of extrahepatic nodal or non-nodal metastases;
• Immunotherapy or chemotherapy ≤ 6 weeks prior to the procedure;
• Any surgical resection or focal ablative liver therapy for CRLM prior to inclusion

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Surgical resection; Patients included will undergo resection of hepatic metastases, allowing thermal ablation for additional unresectable lesions.	Procedure: Surgical resection; In case of randomization to surgical resection, the surgeon will remove all target lesions as well as all additional unablatable lesions.
Experimental: Thermal ablation; Patients included will undergo ultrasound guided thermal ablation of hepatic metastases, allowing resection for additional unablatable lesions.	Procedure: Thermal ablation; Patients will undergo either radiofrequency ablation (RFA) or microwave ablation (MWA).; Other Names: RFA; Radiofrequency ablation; Microwave ablation; MWA

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall survival (OS)	Counting from the date of randomization to the date of death of the patient or to the last day of follow-up.	5 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Disease free survival	The time from focal therapy to the time of events.	5 years
Time to progression	The time from focal therapy to the time of events.	5 years

Collaborators and Investigators

• Sponsor: Amsterdam UMC, location VUmc
• Collaborators: Medtronic - MITG
• Investigators: Principal Investigator: MR Meijerink, MD, PhD, VU University Medical Center, Amsterdam, NL

Publications and helpful links

General Publications

• Puijk RS, Ruarus AH, Vroomen LGPH, van Tilborg AAJM, Scheffer HJ, Nielsen K, de Jong MC, de Vries JJJ, Zonderhuis BM, Eker HH, Kazemier G, Verheul H, van der Meijs BB, van Dam L, Sorgedrager N, Coupe VMH, van den Tol PMP, Meijerink MR; COLLISION Trial Group. Colorectal liver metastases: surgery versus thermal ablation (COLLISION) - a phase III single-blind prospective randomized controlled trial. BMC Cancer. 2018 Aug 15;18(1):821. doi: 10.1186/s12885-018-4716-8.

Study record dates

Study Major Dates

• Study Start (Actual): July 13, 2017
• Primary Completion (Anticipated): July 1, 2024
• Study Completion (Anticipated): December 1, 2024

Study Registration Dates

• First Submitted: January 11, 2017
• First Submitted That Met QC Criteria: March 22, 2017
• First Posted (Actual): March 23, 2017

Study Record Updates

• Last Update Posted (Actual): December 20, 2022
• Last Update Submitted That Met QC Criteria: December 18, 2022
• Last Verified: December 1, 2022

More Information

Terms related to this study

• Keywords: Thermal ablation; Radiofrequency ablation; RFA; Microwave ablation; Hepatic resection; Liver surgery; MWA
• Additional Relevant MeSH Terms: Digestive System Diseases; Pathologic Processes; Neoplasms; Neoplasms by Site; Digestive System Neoplasms; Liver Diseases; Neoplastic Processes; Neoplasm Metastasis; Liver Neoplasms; Neoplasms, Second Primary
• Other Study ID Numbers: NL58551.029.16

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No